$7.65
0.121.59%
Last update: Nov 11, 6:13 PM
BioCryst Pharmaceuticals Inc
BCRXNASDAQ
BioCryst Pharma (BCRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $0.14 | $0.11 | 27.3 % |
| Q2 | Aug 5, 2026 | $0.30 | $0.22 | 36.4 % |
| Q1 | May 6, 2026 | $0.14 | $0.10 | 40.0 % |
| Q4 | Feb 26, 2026 | $0.06 | $0.07 | -21.4 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $180.29M | $165.83M | 8.72 % |
| Q2 | Aug 5, 2026 | $218.25M | $187.77M | 16.2 % |
| Q1 | May 6, 2026 | $156.41M | $152.16M | 2.79 % |
| Q4 | Feb 26, 2026 | $163.28M | $150.54M | 8.46 % |
BioCryst Pharma (BCRX) last issued guidance on November 4, 2026 for fiscal year 2026. The company guided revenue in the range of $715M - $730M for the period.
Compared to prior guidance, BioCryst Pharma raised its revenue forecast from a prior range of $690M - $715M.
BioCryst Pharma has issued 12 guidance updates between January 10, 2025 and November 4, 2026. During this period, the company raised its outlook 6 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.11 | $0.22 | $0.10 | $0.07 |
| Actual | $0.14 | $0.30 | $0.14 | $0.06 |
| Surprise | +27.3% | +36.4% | +40.0% | -21.4% |
| Revenue | ||||
| Estimate | $165.8M | $187.8M | $152.2M | $150.5M |
| Actual | $180.3M | $218.3M | $156.4M | $163.3M |
| Surprise | +8.72% | +16.2% | +2.79% | +8.46% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.10 | $0.16 | $0.14 | $0.16 |
| Revenue | ||||
| Consensus | $166.2M | $165.5M | — | — |
